Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats by Chang, Chia Ju et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 787152, 11 pages
doi:10.1155/2012/787152
Research Article
Myricetin Increases Hepatic Peroxisome Proliferator-Activated
Receptor α Protein Expression andDecreasesPlasma Lipidsand
Adiposity inRats
ChiaJuChang,1 Thing-FongTzeng,2 Shorong-ShiiLiou,3 Yuan-ShiunChang,1 andI-MinLiu3
1School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan
2Department of Internal Medicine, Pao Chien Hospital, Pingtung City, Pingtung County, Taiwan
3Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Yanpu Township,
Pingtung County, Taiwan
Correspondence should be addressed to Yuan-Shiun Chang, yschang@mail.cmu.edu.tw and I-Min Liu, iml@mail.tajen.edu.tw
Received 25 August 2011; Accepted 7 December 2011
Academic Editor: Carlo Ventura
Copyright © 2012 Chia Ju Chang et al. This is an open access article distributed under the Creative Commons AttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The aim of this study was to investigate the antiobesity and antihyperlipidaemic eﬀects of myricetin. Myricetin exhibited a
signiﬁcant concentration-dependent decrease in the intracellular accumulation of triglyceride in 3T3-L1 adipocytes. The high-
fat diet (HFD)-fed rats were dosed orally with myricetin or fenoﬁbrate, once daily for eight weeks. Myricetin (300mgkg−1 per
day) displayed similar characteristics to fenoﬁbrate (100mgkg−1 per day) in reducing lowered body weight (BW) gain, visceral
fat-pad weights and plasma lipid levels of HFD-fed rats. Myricetin also reduced the hepatic triglyceride and cholesterol contents,
as well as lowered hepatic lipid droplets accumulation and epididymal adipocyte size in HFD-fed rats. Myricetin and fenoﬁbrate
reversed the HFD-induced down-regulation of the hepatic peroxisome proliferator activated receptor (PPAR)α. HFD-induced
decreases of the hepatic protein level of acyl-CoA oxidase and cytochrome P450 isoform 4A1 were up-regulated by myricetin and
fenoﬁbrate. The elevated expressions of hepatic sterol regulatory element binding proteins (SREBPs)of HFD-fed rats were lowered
by myricetin and fenoﬁbrate. These results suggest that myricetin suppressed BW gain and body fat accumulation by increasing
the fatty acid oxidation, which was likely mediated via up-regulation of PPARα and down-regulation of SREBP expressions in the
liver of HFD-fed rats.
1.Introduction
Obesity is a common chronic disorder of carbohydrate and
fat metabolism which is characterized by excessive fat depo-
sition in adipose tissue and other internal organs such as
liver, heart, skeletal muscle, and pancreatic islet [1]. Obesity
remains a major global public health issue because of its
increasing prevalence, cutting across all sex, age-groups,
ethnicity, or race [1]. Obesity alone can induce all symptoms
of metabolic syndrome, which is associated with many ad-
ditional health problems, including increased risk of insulin
resistance, nonalcoholic fatty liver, atherosclerosis, degener-
ative disorders such as dementia, some immune mediated
disorders such as asthma, and certain cancers [2]. Phar-
m a c o l o g i c a la p p r o a c h e st ow e i g h tc o n t r o lh a v eb e c o m ea n
overriding priority [3]. Current trends for obesity manage-
ment involve multiple pharmacological strategies including
blocking nutrient absorption, modulating fat metabolism,
regulating adipose signals, and modulating the satiety center,
however, several serious adverse eﬀects in clinic, including
gastrointestinal adverse eﬀect and signiﬁcant unfavorable ef-
fects on cardiovascular system [3]. As a result, much safer
therapeutic is necessary.
Currently, there is growing interest in the therapeutic
applications of bioﬂavonoids and other naturally occurring
polyphenols for the treatment and prevention of diseases in
humans. Myricetin (3, 5, 7, 3 ,4  ,5  -hexahydroxyﬂavone) is
a naturally occurring ﬂavonoid that is commonly found in
tea,berries,fruits,vegetables,andmedicinalherbs.Myricetin
has been shown to possess antioxidative and cytoprotective2 Evidence-Based Complementary and Alternative Medicine
properties [4, 5]. A therapeutic eﬀect of myricetin in patients
withcardiovasculardiseasesassociatedwithdiabetesmellitus
has also been reported [4, 5]. Myricetin has also demon-
strated the ability to improve glucose utilization, lowering
plasma-glucose levels in a type 1 diabetes-like animal model
[6]. Furthermore, myricetin displays the characteristics of
rosiglitazone, demonstrating improved glucose utilization
and ameliorating the impaired insulin-signaling pathway in
insulin-resistant rats induced by the high intake of fructose
[7]. Although myricetin has been found to reduce hypergly-
cemia in diabetic rats, possibly through its ability to increase
hepatic glycogen synthesis and to normalize hypertriglyc-
eridemia [8], insuﬃcient information is available regarding
the eﬀect of myricetin on the regulation of lipid disorders.
Diet-induced obesity in rodents has been used as an ani-
mal model to investigate interactions between the environ-
ment and genetics. Rats fed a high-fat diet (HFD) become
obese and show distinctive visceral adiposity, dyslipidemia,
hyperinsulinemia, and hepatic steatosis, which are typically
associated with human obesity [9]. Therefore, a rat model
of diet-induced obesity can be used to investigate the eﬀects
of antiobesity agents. This study investigated the eﬀects
of myricetin on body fat and lipid proﬁles in rats with
diet-induced obesity and sought possible mechanisms of
action.
2. Methods
2.1. Cell Culture. 3T3-L1 preadipocytes, obtained from Bi-
oresource Collection and Research Center (BCRC 60159)
of the Food Industry Research and Development Institute
(Hsinchu, Taiwan), were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) (GIBCO BRL Life Technologies,
Invitrogen Corporation, CA, USA) with 10% fetal bo-
vine serum (FBS) (GIBCO BRL) and antibiotics (100
units mL−1 penicillin and 100μgmL −1 streptomycin). When
c e l l sw e r ec o n ﬂ u e n t ,d i ﬀerentiation was induced by adding
0.5mmolL−1 isobutylmethylxanthine (Sigma-Aldrich Co.,
S t .L o u i s ,M O )a n d1 μmolL−1 dexamethasone (Sigma-
Aldrich Co.) to the cultures. After 2 days cells were allowed
to diﬀerentiate further by adding 10% FBS and 10μgmL −1
insulin (Sigma-Aldrich Co.) and the medium was changed
every 2 days. At day 10, about 80% of cultures were induced
to contain triglyceride (TG). Treatments including serum
starvation (DMEM only), myricetin (purity ≥97.0%; Sigma-
Aldrich Co.), or fenoﬁbrate (purity ≥99.0%; Sigma-Aldrich
C o . )w e r eg i v e nt od i ﬀerentiated cultures for 8 hours. All
o t h e rr e a g e n t sw e r eo fa n a l y t i c a lg r a d e .
2.2. Measurement of the Triglyceride Content. Oil Red O
(Sigma-Aldrich Co.) at 0.2% in isopropanol (Sigma-Aldrich
Co.) was mixed with water (3:2, vv−1) and ﬁltered.
Experimental cultured cells were washed with PBS, ﬁxed by
paraformaldehyde (4% in PBS, (Sigma-Aldrich Co.) for 5
minutes, incubated with ﬁltered Oil Red O for 30 minutes,
and washed twice with PBS. The stained TG was extracted
by isopropanol and its quantity was measured at 490nm
absorbance [10].
2.3. Animal Models and Treatment Protocols. Male Wistar
rats aged 8 weeks were obtained from the National Labora-
tory Animal Center (Taipei, Taiwan). They were maintained
in a temperature-controlled room (25 ± 1◦C) and kept on
a 12:12 light-dark cycle (lights on at 06:00h) in our animal
center. Food and water were available ad libitum. Regular rat
diet (RCD) (11kcal% fat number LM-485, Teklad, Madison,
WI) was used as the maintenance and control diet. A
puriﬁed ingredient HFD with 45kcal% fat primarily from
lard (number D12451, Research Diets, New Brunswick, NJ)
was used to induce a rapid increase in body weight (BW)
and obesity [11]. The caloric density of the control diet was
3.4kcalg−1; that of the HFD was 4.73kcalg−1, resulting in
lower daily food consumption in grams for the rats fed the
HFD. All animal procedures were performed according to
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health, as well as the guidelines of the
Animal Welfare Act.
After being fed an HFD for 2 weeks, myricetin was dis-
solved in distilled water for oral gavage administration at
the desired doses (75, 150, and 300mgkg−1 per day) in
av o l u m eo f2 m L k g −1 once a day into the HFD-fed rats.
Another group of HFD-fed was treated by oral gavage with
100mgkg−1 per day of fenoﬁbrate for 8 weeks. The dose of
fenoﬁbrate was chosen according to other studies with long-
term fenoﬁbrate treatment in rats [12]. A further group of
HFD-fed and RCD-fed rats were treated similarly but with
the same volume of vehicle (distilled water) as was used to
dissolve the tested compounds during the same treatment
period. Eight animals were used for each experimental
group. Water was made available ad libitum throughout the
experiment.
Eight weeks after the treatment, rats were weighed and
blood samples were collected from the lateral tail vein
of the animals anesthetized with sodium pentobarbital
(30mgkg−1) administered intraperitoneally (i.p.). Samples
werecentrifugedat2,000gfor10minutesat4◦C.Theplasma
was then removed and placed into aliquots for the respec-
tive analytical determinations. The liver and visceral and
subcutaneous white adipose tissues (WAT) were removed
after blood was collected, rinsed with a physiological saline
solution, weighed, and immediately stored at −70◦C.
2.4. Biochemical Parameter Analysis. The diagnostic kits for
determinations for plasma glucose (Cat. No. 10009582),
total cholesterol (TC; Cat. No. 10007640) and triglyceride
(TG; Cat. No. 10010303) were purchased from Cayman
Chemical Company (Michigan, USA). The diagnostic kit for
determinations for plasma levels of high-density lipopro-
tein cholesterol (HDL-C) was purchased from Bio-Quant
Diagnostics (CA, USA; Cat. No. BQ 019CR), low-density
lipoprotein cholesterol (LDL-C) was calculated by using
Friedewald’s equation [13]. Plasma level of free fatty acids
(FFAs) was determined by the FFAs quantiﬁcation kit
obtained from Abcam plc. (MA, USA; Cat. No. ab65341). All
samples were analyzed in triplicate. Atherogenic index (AI)
and coronary risk index (CRI) were calculated as follows:
LDL-C/HDL-C and TC/HDL-C [14, 15], respectively.Evidence-Based Complementary and Alternative Medicine 3
2.5. Extraction of Hepatic Lipids. After removal from the
animals, part of the samples of fresh liver was collected for
analyzing the lipid contained. Liver (1.25g) was homoge-
nized with chloroform/methanol (1:2, 3.75mL), and then
chloroform (1.25mL) and distilled water (1.25mL) were
added to the homogenate and mixed well. After centrifu-
gation (1,500g for 10min), the lower clear organic phase
solution was transferred into a new glass tube and then
lyophilized. The lyophilized powder was dissolved in chloro-
form/methanol (1:2) as the hepatic lipid extracts and stored
at −20◦C for less than 3 days [16]. The hepatic cholesterol
and triglycerides in the lipid extracts were analyzed with the
diagnostic kits which were used in the plasma analysis.
2.6. Hepatic Pathological Evaluation. Small pieces of hepatic
tissues taken from experimental animals were ﬁxed in 10%
neutral formalin, alcohol-dehydrated, paraﬃn-embedded,
and sectioned to a mean thickness of 4μm. The histological
examination by the aforementioned conventional methods
was evaluated for the index of diabetic-induced necrosis by
assessing the morphological changes with hematoxylin and
eosin (H&E) stain. Liver biopsy was scored according to
the criteria as follows [17] :g r a d e0 :n os t e a t o s i s ,n o r m a l
liver; grade 1: <25% of hepatocytes aﬀected; grade 2: 26–
50% of hepatocytes aﬀected; grade 3: 51–75% of hepatocytes
aﬀected; and grade 4: >76% of hepatocytes aﬀected.
2.7. Adipocyte Pathological Evaluation. Histological photo-
graph of adipose tissue was analyzed based on the paraﬃn
method using a light microscope. Fresh tissues were ﬁxed
immediately in Bouin’s solution for 6–12 hours and then
ﬁxed tissue was washed under running water. After being
dehydrated through diﬀerent grades of alcohol, the tissues
were embedded in paraﬃnb l o c ka t6 0 ◦C. Eight μms e c t i o n s
were cut and mounted on glass slides coated with an egg
albumin and then the paraﬃnw a sr e m o v e dw i t hx y l e na n d
alcohol. The glass slides were stained with H&E. After being
dehydrated and cleared by alcohol and xylen, the glass slides
were mounted in Canada Balsam. Photomicrographs were
taken with a Zeiss Axiolab light microscope equipped with
a Nikon Microﬂex HFX microscope camera. The size of
epididymal adipocyte was calculated by Image-Pro Plus 7.0
(Media Cybernetics, MD, USA).
2.8. Preparation of Hepatic Fractions. To prepare nuclear
fractions, hepatic tissue was homogenized with ice-cold lysis
buﬀercontaining5mmolL−1 Tris-HCl(pH7.5),2mmolL−1
MgCl2, 15mmolL−1 CaCl2, and 1.5molL−1 sucrose, and
then 0.1molL−1 dithiothreitol (DTT) and protease inhibitor
cocktail were added. After centrifugation (10,500 ×gf o r
20min at 4◦C), the pellet was suspended with extrac-
tion buﬀer containing 20mmolL−1 2-[4-(2-hydroxyethyl)-
1-piperazinyl]ethanesulfonic acid (pH 7.9), 1.5mmolL−1
MgCl2,0 . 4 2 m o l L −1 NaCl, 0.2mmolL−1 EDTA, and 25%
(vv−1) glycerol, and then 0.1molL−1 DTT and protease
inhibitor cocktail were added. The mixture was placed on ice
for 30min. The nuclear fraction was prepared by centrifuga-
tion at 20,500 xg for 5min at 4◦C. The postnuclear fraction
was extracted from the liver of each mouse as described
here in after. In brief, hepatic tissue was homogenized
with ice-cold lysis buﬀer (pH 7.4) containing 137mmolL−1
NaCl, 20mmolL−1 Tris-HCl, 1% Tween 20, 10% glycerol,
1mmolL−1 phenylmethylsulfonylﬂuoride(PMSF),andpro-
tease inhibitor mixture DMSO solution. The homogenate
was then centrifuged at 2,000 ×gf o r1 0m i na t4 ◦C. The pro-
tein concentration of each fraction was determined using a
commercial kit (Bio-Rad Laboratories, Hercules, CA, USA).
2.9. Western Blot Analyses. For the determination of perox-
isome proliferator-activated receptor (PPAR), sterol regula-
tory element binding protein- (SREBP-) 1, and SREBP-2,
30mg protein of each nuclear fraction was electrophoresed
through8%sodiumdodecylsulfatepolyacrylamidegel(SDS-
PAGE). Separated proteins were electrophoretically trans-
ferred to a nitrocellulose membrane, blocked with 5%
(wv−1) skim milk solution for 1h, and then incubated with
primary antibodies to PPARα (Santa Cruz Biotechnology,
Inc., CA, USA; Cat. No. sc-1985), SREBP-1 (Santa Cruz
Biotechnology, Inc.; Cat. No. sc-367), SREBP-2 (Santa Cruz
Biotechnology, Inc.; Cat. No. sc-5603), and β-actin (Santa
Cruz Biotechnology, Inc.; Cat. No. sc-130656), respectively,
overnight at 4◦C. After the blots were washed, they were
incubated with goat anti-rabbit and/or goat anti-mouse IgG
HRP-conjugated secondary antibody for 1.5h at room tem-
perature.Also,30mgproteinofeachpostnuclearfractionfor
acyl-CoAoxidase(ACO;SantaCruzBiotechnology,Inc.;Cat.
No. sc-98499) and cytochrome P450 isoform 4A1 (CYP4A1;
Santa Cruz Biotechnology, Inc.; Cat. No. sc-53248) was
electrophoresed through 10% SDS-PAGE. Each antigen-
antibodycomplexwasvisualizedusingECLWesternBlotting
DetectionReagentsanddetectedbychemiluminescencewith
LAS-1000 plus (Fujiﬁlm, Tokyo, Japan). Band densities were
determinedusingATTODensitographSoftware(ATTOCor-
poration,Tokyo,Japan)andquantiﬁedastheratiotoβ-actin.
The mean value for samples from the vehicle-treated RCD-
fed group on each immunoblot, expressed in densitometry
units, was adjusted to a value of 1.0. All experimental sample
values were then expressed relative to this adjusted mean
value.
2.10. Statistical Analysis. All data represented as the mean ±
SEM. Statistical diﬀerences among groups were determined
by using two-way repeated-measures ANOVA. The Dunnett
range post hoc comparisons were used to determine the
source of signiﬁcant diﬀerences where appropriate. A P value
<.05 was considered statistically signiﬁcant.
3. Results
3.1.EﬀectsonTriglyceride(TG)Contentin3T3-L1Adipocytes.
The TG content of diﬀerentiated 3T3-L1 adipocytes treated
with myricetin was measured. It exhibited a signiﬁcant dose-
dependent decrease in the intracellular accumulation of
TG in 3T3-L1 adipocytes; the most signiﬁcant eﬀect (over
30% TG reduction) was observed in myricetin treatment
at 1μmolL−1 (Figure 1). Fenoﬁbrate (1μmolL−1)c a u s e da4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀect of myricetin or fenoﬁbrate on triglyceride (TG) content in 3T3-L1 adipocytes. (a) Microscopic (40x magniﬁcation)
images of oil red O-stained adipocytes. Photomicrographs are of tissues isolated from vehicle-treated 3T3-L1 adipocytes (vehicle),
myricetin-(0.001μmolL−1)treatedadipocytes(myricetin0.001),myricetin-(0.01μmolL−1)treatedadipocytes(myricetin0.01),myricetin-
(0.1μmolL−1)treatedadipocytes(myricetin0.1),myricetin(1.0μmolL−1)-treatedadipocytes(myricetin1.0),orfenoﬁbrate-(1.0μmolL−1)
treated adipocytes (fenoﬁbrate 1.0). The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. (b)
Quantiﬁcation of oil red O staining. The experiments were performed in at least 4 replicates per treatment. Values were expressed as mean
with SEM (n = 4 per group) in each column. aP<. 05 and bP<. 01 compared to the values of vehicle-treated group.
decrease in the TG content of diﬀerentiated 3T3-L1 adipo-
cytes by 41% (Figure 1).
3.2. Eﬀects on Body Weight (BW) and Food Intake. All the
measurementsweredoneafter8weeksoftreatment.TheBW
of myricetin-treated rats was signiﬁcantly lower than that of
rats in the HFD group (Table 1) .T h em o d e r a t e( 1 5 0m gk g −1
per day) and high doses (300mgkg−1 per day) of myricetin
signiﬁcantly suppressed BW gain; similar results were seen in
rats treated with fenoﬁbrate (100mgkg−1 per day; Table 1).
No signiﬁcant diﬀerences were observed in daily food
intake among all the groups during whole experimental
period, despite the water intake became slightly higher in
vehicle-treated HFD-fed group as compared to the others
(Table 1).
3.3. Eﬀects on Fat Pad Weight. The weights of epididymal
WAT, perirenal WAT, mesenteric WAT, and inguinal WAT
were decreased by 22.2%, 25.1%, 24.4%, and 28.1%, respec-
tively, in myricetin-treated HFD-fed rats compared with
their vehicle-treated counterparts (Table 2). The increase
in epididymal, perirenal, mesenteric, and inguinal fat padsEvidence-Based Complementary and Alternative Medicine 5
Table 1: Changes on the body weight (BW) and food and water intake in HFD-fed rats receiving 8-weeks treatment with myricetin or
fenoﬁbrate.
Variable (s) RCD-fed HFD-fed
Vehicle Vehicle Myricetin (mg kg−1 per day) Fenoﬁbrate
75 150 300 (100mgkg−1 per day)
Initial BW (grat−1) 172.5 ±7.7 173.4 ±6.9 171.4 ±7.1 170.3 ±7.8 173.6 ±6.5 172.3 ±6.7
BW gain (grat−1) 17.8 ± 6.2d 50.7 ± 7.0b 41.4 ± 6.7b 30.7 ± 6.9a,c 23.6 ± 5.3d 19.3 ± 5.5d
Food intake (grat−1 per day) 19.3 ±5.92 0 .3 ±6.71 9 .8 ±6.52 0 .7 ±6.62 0 .3 ± 7.81 9 .9 ±7.1
Water intake (mLrat−1 per day) 67.2 ± 8.1c 88.3 ± 7.4a 82.4 ±9.2a 80.8 ±9.7a 78.1 ±7.9c 76.7 ± 8.9c
Myricetin or fenoﬁbrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2mLkg−1 once a day into HFD-fed rats.
The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. aP < .05 and bP<
.01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. cP<. 05 and dP<. 01 compared to the values of vehicle-treated HFD-
fed rats in each group, respectively.
Table 2: Changes in the fat-pad weight in HFD-fed rats receiving 8-weeks treatment with myricetin or fenoﬁbrate.
Variable (s) RCD-fed HFD-fed
Vehicle Vehicle Myricetin (mg kg−1 per day) Fenoﬁbrate
75 150 300 (100mgkg−1 per day)
Epididymal WAT (mg 100g BW−1) 285.4 ± 12.7d 396.8 ± 15.6b 368.1 ± 16.1a 338.5 ± 22.8a,c 308.4 ± 19.2a,c 293.9 ± 14.6d
Perirenal WAT (mg 100g BW) 162.5 ± 11.6d 247.9 ± 12.1b 228.6 ±13.5 198.9 ±13.9a,c 185.3 ± 12.1c 170.2 ± 11.7d
Mesenteric WAT (mg 100g BW) 122.1 ± 8.8c 180.2 ± 11.5a 171.5 ± 13.1a 156.2 ± 10.3a 136.9 ± 8.7c 125.6 ± 9.2c
Inguinal WAT (mg 100g BW) 138.0 ± 10.3c 210.2 ± 12.8a 194.3 ± 11.8a 170.6 ±11.0a,c 151.1 ± 9.2c 142.2 ± 10.5c
Myricetin or fenoﬁbrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2mLkg−1 once a day into HFD-fed rats.
The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. aP<. 05 and
bP<. 01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. cP<. 05 and dP<. 01 compared to the values of vehicle-treated
HFD-fed rats in each group, respectively.
weight in HFD-fed rats was also lower in fenoﬁbrate-treated
group compared with the vehicle-treated counterparts.
3.4. Eﬀects on Plasma Lipids. The HFD caused the ele-
vation of plasma TC, TG, and LDL-C concentrations in
r a t s .T h em o d e r a t e( 1 5 0 m g k g −1 per day) and high doses
(300mgkg−1 per day) of myricetin signiﬁcantly decreased
the level of plasma TC (23.8% and 31.4% reduction, resp.)
compared with vehicle-treated, HFD-fed rats (Table 3). All
doses of myricetin decreased the level of plasma TG in HFD-
fed rats (Table 3). The low (75mgkg−1 per day), moderate
(150mgkg−1 per day), and high doses (300mgkg−1 per day)
of myricetin signiﬁcantly reduced plasma levels of LDL-
C (17.5%, 36.8%, and 51.9% reductions, resp.) (Table 3).
PlasmaTC,TG,andLDL-Cconcentrationsweresigniﬁcantly
lower by 41.1%, 51.2%, and 60.1%, respectively, in fenoﬁ-
brate (100mgkg−1 per day) treated, HFD-fed rats compared
with vehicle-treated, HFD-fed rats (Table 3).
Plasma level of HDL-C in HFD-fed rats was lower
to 57.8% of that in the RCD-fed group (Table 3). Lower
plasma level of HDL-C in HFD-fed rats receiving myricetin
(300mgkg−1 per day) or fenoﬁbrate- (100mgkg−1 per day)
treatment was elevated to nearly that of RCD-fed group.
The plasma FFAs were signiﬁcantly higher in HFD-fed
rats receiving vehicle (Table 3). The plasma FFA was lower
by 39.3% in myricetin- (300mgkg−1 per day) treated HFD-
fed rats as compared with the vehicle-treated counterparts
(Table 3). FFA concentrations in HFD-fed rats were signiﬁ-
cantly lower by 46.4% in fenoﬁbrate- (100mgkg−1 per day)
treated, HFD-fed rats compared with vehicle-treated, HFD-
fed rats (Table 3).
Fenoﬁbrate treatment (100mgkg−1 per day) arrested the
elevation of AI and CRI in HFD-fed rats (Table 3). Myricetin
treatmentalsocausedasigniﬁcant(P<. 05)anddose-related
reduction in the atherogenic and coronary artery risk indices
in the HFD-fed rats when compared to the values recorded
for the vehicle-treated counterparts (Table 3).
3.5. Eﬀects on Hepatic Lipids. The hepatic TC level was
signiﬁcantly higher in HFD-fed rats than that in the RCD-
fed group; those were lower by 34.6% in the myricetin-
(300mgkg−1 per day) treated group (Table 3). HFD-fed rats
receiving treatment with myricetin (300mgkg−1 per day)
alsoshowedsigniﬁcantlylowervaluesofhepaticTGto65.7%
as compared with the vehicle-treated counterparts (Table 3).
Hepatic TC and TG levels were signiﬁcantly lower by 40.3%
and 41.6%, respectively, in fenoﬁbrate (100mgkg−1 per day)
treated rats compared with vehicle-treated, HFD-fed rats
(Table 3).
3.6. Morphological Changes in Hepatocytes. HFD-fed rats
showed considerable hepatic lipid accumulation compared
with that in RCD-fed group (Figure 2). The extent of6 Evidence-Based Complementary and Alternative Medicine
Table 3:Changesintheplasmaandhepaticlipids,atherogenicindex(AI),andcoronaryarteryindex(CRI)inHFD-fedratsreceiving8-week
treatment with myricetin or fenoﬁbrate.
Variable (s) RCD-fed HFD-fed
vehicle Vehicle Myricetin (mg kg−1 per day) Fenoﬁbrate
75 150 300 (100mgkg−1 per day)
Plasma TC (mg dL−1) 71.4 ± 6.7d 143.2 ± 11.9b 128.4 ± 9.5b 109.6 ± 7.7a,c 98.3 ± 7.3a,c 84.2 ± 8.0d
Plasma TG (mg dL−1) 55.7 ± 5.9d 134.5 ± 5.7b 116.4 ± 6.1b 99.8 ± 4.7b,c 84.3 ±4.3b,c 65.6 ±4.7d
Plasma LDL-C (mg dL−1) 31.2 ± 3.3d 103.2 ± 3.9b 84.9 ± 5.3b,c 66.2 ± 4.7b,c 49.5 ±4.1a,d 40.4 ± 4.3d
Plasma HDL-C (mg dL−1) 45.6 ± 3.1d 26.4 ± 3.2b 30.5 ± 3.5b 37.1 ± 2.9a,c 41.7 ± 3.1d 43.6 ± 4.4d
Plasma FFAs (mg dL−1) 27.6 ± 2.7d 63.8 ± 4.1b 56.9 ± 4.3b 48.5 ± 3.8b,c 38.7 ± 3.2a,d 34.2 ± 3.5d
Hepatic TC (mg g−1)2 . 6 ± 0.8d 5.2 ± 0.7b 4.6 ± 0.5b 4.3 ± 0.4a 3.4 ± 0.3c 3.1 ± 0.5c
Hepatic TG (mg g−1)9 . 0 ± 1.1d 19.0 ± 1.2b 17.8 ± 1.4b 17.2 ± 1.1a 12.5 ± 1.2c 11.1 ± 0.8c
AI 0.7 ± 0.2d 3.9 ± 0.2b 2.8 ± 0.1b 1.8 ±0.3a,c 1.2 ± 0.2a,d 0.9 ± 0.3d
CRI 1.6 ± 0.2d 5.5 ± 0.6b 4.2 ±0.5b 2.9 ±0.4a,c 2.2 ± 0.3d 1.9 ± 0.4d
Myricetin or fenoﬁbrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2mLkg−1 once a day into HFD-fed rats.
The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. aP<. 05 and bP<
.01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. cP<. 05 and dP<. 01 compared to the values of vehicle-treated HFD-
fed rats in each group, respectively.
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Figure 2: Histopathological ﬁndings in livers of HFD-fed rats receiving 8-week treatment with myricetin or fenoﬁbrate. Rats not receiving
any treatment were given the same volume of vehicle (distilled water) used to dissolve the test medications. Photomicrographs are of tissues
isolated from vehicle-treated RCD-fed rats (vehicle-RCD), vehicle-treated HFD-fed rats (vehicle-HFD), myricetin- (300mgkg−1 per day)
treated HFD-fed rats (myricetin-HFD), or fenoﬁbrate- (100mgkg−1 per day) treated HFD-fed rats (fenoﬁbrate-HFD). Photomicrographs
were taken at a magniﬁcation of ×400.
hepatic lipid accumulation in fenoﬁbrate-treated HFD-
fed rats was similar to those in RCD-fed rats (Figure 2).
HFD-fed rats receiving treatment with myricetin at the
daily dose of 300mgkg−1 showed considerably lower
hepatic lipid accumulation than in their vehicle-treated
counterparts (Figure 2). The pathological grading of hep-
atic steatosis in HFD-fed rats was 3.2 ± 0.4, which was
reduced to 1.8 ± 0.6a n d1 .2 ± 0.3 after receiving treat-
ment with myricetin (300mgkg−1 per day) or fenoﬁbrate,
respectively.
3.7. Morphological Changes in Epididymal Adipocytes. The
histological appearance of epididymal adipocyte was irreg-
ular in HFD-fed rats compared to RCD-fed group; this mor-
phological change did not appear in HFD-fed groups after
fenoﬁbratetreatment(Figure 3).Thehistologicalappearance
of epididymal adipocyte was more regular in HFD-fed rats
treated with myricetin (300mgkg−1 per day). In addition,
the sizes of epididymal adipocytes were signiﬁcantly bigger
in HFD-fed group compared to RCD-fed group (Figure 3).
TheaveragesizeofepididymaladipocyteswasapproximatelyEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: Histopathological ﬁndings in epididymal white adipose tissue of HFD-fed rats receiving 8-week treatment with myricetin or
fenoﬁbrate. Rats not receiving any treatment were given the same volume of vehicle (distilled water) used to dissolve the test medications.
(a) Photomicrographs were taken at a magniﬁcation of ×400. Photomicrographs are of tissues isolated from vehicle-treated RCD-fed rats
(vehicle-RCD), vehicle-treated HFD-fed rats (vehicle-HFD), myricetin- (300mgkg−1 per day) treated HFD-fed rats (myricetin-HFD), or
fenoﬁbrate- (100mgkg−1 per day) treated HFD-fed rats (fenoﬁbrate-HFD). (b) The size of adipocytes in a ﬁxed area (1,000,000μm2)w a s
measured. All values are expressed as mean with SEM (n = 5 per group) in each column. aP<. 05 compared to the values of vehicle-treated
HFD-fed group.
lower by 25.6% and 32.4%, respectively, in myricetin-
(300mgkg−1 per day) or fenoﬁbrate- (100mgkg−1 per day)
treated HFD-fed rats as compared with the vehicle-treated
counterparts (Figure 3).
3.8. Protein Expressions of PPARα,A C O ,C Y P 4 A ,a n dS R E B P s
in Hepatic Tissues. The hepatic PPARα protein expression of
HFD-fed rats was lower than those of the RCD-fed group
but signiﬁcantly elevated by myricetin (300mgkg−1 per day)
treatment (Figure 4(a)). In addition, the protein expressions
of hepatic ACO and CYP4A in HFD-fed rats were markedly
lower than that of RCD-fed group but signiﬁcantly elevated
in myricetin- (300mgkg−1 per day) treated HFD-fed rats
(Figure 4(b)). Similar results were seen in rats treated with
fenoﬁbrate (100mgkg−1 per day).
The protein expressions of hepatic SREBP-1 and
SREBP-2 in HFD-fed rats were signiﬁcantly higher than
those of RCD-fed group, respectively. The HFD-fed rats8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Representative immunoblots of protein expression of (a) PPARα, (b)ACO and CYP4A, and (c) SREBPs in livers of HFD-fed rats
receiving8-weektreatmentwithmyricetin(300mgkg−1 perday)orfenoﬁbrate(100mgkg−1 perday).Ratsnotreceivinganytreatmentwere
given the same volume of vehicle (distilled water) used to dissolve the test medications. Similar results were obtained with an additional 4
replications. Quantiﬁcation of protein levels was expressed as mean with SEM (n = 5 per group) in each column. aP<. 05 compared to the
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treated with fenoﬁbrate (100mgkg−1 per day) had hepatic
SREBP-1 and SREBP-2 protein expression levels that were
48.6% and 40.2%, respectively, lower than those in vehicle-
treated counterpart (Figure 4(c)). Hepatic SREBP-1 and
SREBP-2 protein expression levels in HFD-fed rats after
myricetin (300mgkg−1 per day) treatment were decreased
by 52.3% and 47.3% relative to expression levels in vehicle-
treated HFD-fed rats (Figure 4(c)).
4. Discussion
Adipocytes play an important role in lipid homeostasis and
energy balance by relating to TG storage and free fatty
acids release [18]. The antiobesity eﬀect therefore could be
represented by the suppression of TG formation in 3T3-
L1 adipocytes. Antiobesity eﬀect of myricetin in the 3T3-
L1 cell model was measured in our study. We found that
myricetin treatment reduced TG content up to 30% at the
concentration of 1μmolL−1, which was similar to the eﬀect
produced by fenoﬁbrate at same concentration. PPARα is a
member of the family of nuclear transcription factors that
act as lipid sensors and regulate lipid metabolism [19]. A
PPARα activator, fenoﬁbrate, is known to promote fatty acid
oxidation and to lower circulating lipids and has been used
as a hypolipidemic drug [20].
Several studies have examined the eﬀects of fenoﬁbrate
on daily food intake, body weight, and lipid proﬁle in
rodent models of obesity [21]. Fenoﬁbrate was applied as
the reference drug in this study to investigate the eﬀects
of myricetin on body fat and lipid proﬁles in rats with
diet-induced obesity. In the results of this study, long-
term HFD feeding resulted in obesity, which was associated
with increased BW and fat mass with the development of
hyperlipidemia. Similar to fenoﬁbrate treatment, we found
that administration of myricetin (300mgkg−1 per day) sig-
niﬁcantly suppressed the increase in BW in dietary obese rats
after 8 weeks. This inhibition did not depend on decreased
food or energy intake because all rats in all experimental
groups received an equal diet. The BW loss was accompanied
bydepletionofbodyfatstoressincetreatmentwithmyricetin
also signiﬁcantly reduced the weight of the visceral and
subcutaneous WAT compared with that of the vehicle-
treated HFD-fed group. Excessive growth of adipose tissue
results in obesity which includes two growth mechanisms:
hyperplastic (cell number increase) and hypertrophic (cell
size increase) [22]. The histological appearance of WAT in
HFD-group supplemented with fenoﬁbrate or myricetin was
more regular and showed similar adipocyte size to that of
RCD-group. This suggests that myricetin suppresses HFD-
induced adipose tissue mass and BW gain and may inhibit
lipid accumulation in adipose tissue in particular.
Obesity, especially abdominal obesity, has an associ-
ation with dyslipidemia characterized by increasing TG
and decreasing HDL-C concentrations [23]. Compelling
evidence, from meta-analysis of a number of clinical studies
on a large aggregate of patients, has established an increased
level of TG as an independent risk factor for cardiovascular
disease [24]. TG is involved in the ectopic accumulation of
lipid stores in the liver and is associated with a number of
diseases such as metabolic syndrome and type 2 diabetes.
High TC levels increase the risk of developing coronary
heart disease and high levels of LDL-C are also a risk factor
for coronary heart disease, while high HDL-C is helpful in
transporting excess cholesterol to the liver for excretion in
the bile [25]. As a result, HDL-C levels are inversely related
to this risk [26]. The present study demonstrated that rats
fed an HFD showed a signiﬁcant increase in plasma TC,
TG and LDL-C levels. However, levels of plasma HDL-C in
HFD-fedratsweredecreasedcomparedwiththeRCD-group.
Similar to fenoﬁbrate treatment, the oral administration of
myricetin signiﬁcantly lowered plasma TC, TG, and LDL-C
levelsinratswithHFD-inducedobesity.Thus,myricetinmay
be beneﬁcial for treating patients with hypercholesterolemia
and hypertriglyceridemia.
The eﬀect of myricetin treatment on the atherogenic and
coronary artery risk indices is also notable. The ratio of
total cholesterol to HDL-C (also known as the atherogenic
index) and the ratio of LDL-C to HDL-C (equally known
as coronary artery index) are strong and reliable indicators
of whether or not cholesterol is deposited into tissues
or metabolized and excreted [27]. In this present study,
results showed that treatment with myricetin or fenoﬁbrate
caused profound reductions in the atherogenic and coronary
indices in experimental hyperlipidaemic rats, which strongly
suggested that myricetin has therapeutic potentials in the
management of obesity, hyperlipidaemia, and in the preven-
tion of atherogenic cardiovascular diseases.
Due to the ability of myricetin to reduce serum levels
of TG and TC, as well as adipose tissue mass and BW
gain, which are similar to the function of PPARα activation,
we hypothesized that the function of myricetin is related
the regulation of hepatic expression of PPARα target genes
involved in lipid metabolism. The PPARα is lipid-activated
transcription factor that plays a pivotal role in the tran-
scription regulation of genes involved in lipid catabolism
andlipoproteinmetabolism.Inhepatocytesandothertissues
(e.g., heart), natural long chain fatty acid (ligand) activated
PPARα binds to peroxisome proliferators response element
of DNA and increases the transcription of genes encoding
enzymes involved in fatty acid oxidation and lipoprotein
metabolism [28]. The outcome is an increase in hepatic fatty
acid oxidation and ketogenesis, decreased tissue levels of
lipids, and protection against lipotoxicity. It was found that
myricetin-treated HFD-fed rats had signiﬁcantly higher hep-
atic PPARα protein, which was as eﬀective as that produced
by fenoﬁbrate. It appears that myricetin transcriptionally
increasesPPARαtargetenzymesinthelivers,whichdecreases
the intracellular levels of fatty acids available for TG synthe-
sis; this in turn suppresses plasma TG levels and accumula-
tion of fat [29]. Discovery of myricetin as PPARα activator
may oﬀer promise of a novel class antiobesity candidate.
Although reductions in the lipogenic activity and in
dietary lipid absorption have been suggested as causes of
the reduced liver lipid content, an increased capacity of per-
oxisomal β-oxidation (ACO) and microsomal ω-oxidation
(CYP4A) of fatty acids could also be contributing factors
[28]. Elevated hepatic protein levels of ACO and CYP4A
imply an enhanced fatty acid oxidation in peroxisomes10 Evidence-Based Complementary and Alternative Medicine
and microsomes of myricetin-treated HFD-fed rats. These
results support the contention that myricetin, by directly or
indirectly activating PPARα, can upregulate the expression
of PPARα downstream genes, which may lead to enhanced
hepatic fatty acid oxidation and reduced TG content.
The sterol regulatory element binding proteins (SREBPs)
are a family of three basic helix-loop-helix leucine zipper
transcription factors (SREBP-1a, -1c, and -2) that have been
identiﬁed as transacting factors involved in the maintenance
of intracellular cholesterol homeostasis, the control of fatty
acid metabolism, and the diﬀerentiation of adipocytes [30].
The SREBP-2 isoform activates genes of the cholesterogenic
pathway, whereas the SREBP-1 isoforms are more active
in regulating the synthesis of fatty acids [31]. It has been
documented that SREBPs were the upregulated genes related
tofattyacidsynthaseandcholesterollevels[32].Theelevated
expressions of SREBP-1 and SREBP-2 in HFD-fed rats were
signiﬁcantly decreased by the myricetin (300mgkg−1 per
day) treatment. These results suggest that myricetin has an
ameliorating eﬀect on dyslipidemia through the impaired
hepatic SREBPs as well.
In conclusion, the results of this study showed that my-
ricetin suppressed BW gain and body fat accumulation by
increasingthefattyacidoxidation,whichwaslikelymediated
via upregulation of PPARα and downregulation of SREBP
expressions in the liver of HFD-fed rats. We suggest that
myricetin may prevent or improve obesity by modulating
lipid metabolism and preventing metabolic syndrome as a
representative, lifestyle-related cluster of diseases caused by
an excessively HFD.
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